Home

About Us

Areas Of Practice

Clinical Research

Contact Us

MARK FISHER, M.D., F.A.C.R.
DIPLOMATE, AMERICAN BOARD OF INTERNAL MEDICINE
DIPLOMATE, AMERICAN BOARD OF
INTERNAL MEDICINE SUBSPECIALTY-RHEUMATOLOGY

Education:

1965 – 1969            Rutgers University,

                                New Brunswick, New Jersey

                                B.A. Degree in Biological Sciences

1969 – 1973            Hahnemann Medical College,

                                Philadelphia, PA

                                Doctor of Medicine, M.D., Honors in Medicine

1973 - 1974             Hahnemann Medical College,

                                Philadelphia, PA

                                Straight Medical Internship

1974 - 1976             Hahnemann Medical College,

                                Philadelphia, PA

                                Residency, Internal Medicine

1976 – 1978            Temple University Hospital,

                                Philadelphia, PA

                                Fellowship in Rheumatology

Postgraduate Courses:

Review Course in Rheumatology,

American College of Rheumatology

1978, 1980, 1983, 1987, 1990, 2000, 2003, 2006, 2007, 2009

Immunology for the Non-Immunologist,

Harvard Medical School, 1977

Course in Metabolic Bone Disease,

Peter B. Brigham Hospital, Harvard Medical School,

1977

NYU Seminar in Advanced Rheumatology,

NYU, New York City, NY

1977, 1983, 1986, 1989, 1991, 1993, 1997, 2002, 2004, 2007, 2008

Advances in the Diagnosis and treatment of Rheumatic Diseases

John Hopkins University, Baltimore, MD

2008 & 2008

Annual Seminars:

New Jersey and Philadelphia Rheumatism Societies

American Rheumatism Association National Meeting

Southeastern Regional Meeting,

American College of Rheumatology,

1991

Postgraduate Course in Rheumatology,

University of Pennsylvania,

Philadelphia, Pennsylvania,

1989, 1990, 1991, 1992, 1993 2003 and 2006

American College of Rheumatology 1978, 1980,

1983, 1987, 1990, 2000, 2003, 2006, 2007, 2009

Academic Affiliations:

1979 to present                 Clinical Assistant Professor of Medicine

                                             Thomas Jefferson University Hospital

                                             Philadelphia, Pennsylvania

1978 – 1984                       Coordinator of Junior Medical Student 

                                             Program In Medicine, Our Lady of Lourdes

                                             Medical Center, Camden, New Jersey

1978 – 1979                       Assistant Professor of Medicine

                                             Hahnemann Medical College,

                                             Philadelphia, PA

1976 – 1978                       Instructor in Medicine

                                             Temple University Hospital, Philadelphia, PA

Teaching/Administrative Appointments:

1997 – 1998                       Clinical Studies, New Jersey

1990 to 2009                     Chief, Division of Rheumatology

                                             Kessler Memorial Hospital, Hammonton, NJ

1979 - 1987                        Director of Outpatient Arthritis Service

                                             Our Lady of Lourdes Medical Center,

                                             Camden, NJ

1985 - 2004                        Consultant in Rheumatology

                                             Cooper Hospital/University Medical Center

                                             Camden, New Jersey

1978 – 1984                       Coordinator of Junior Medical Student  

                                             Program In Medicine,
                                             Our Lady of Lourdes Medical Center,

                                             Camden, New Jersey

                                             Teaching/Administrative Appointments       

                                             (continued):

1980 to 2009                      Consultant in Rheumatology Kessler Memorial

                                              Hospital, Hammonton, NJ

1978 to present                  Private Practice

                                              Mark Fisher M.D. F.A.C.R. LLC

                                              713 Station Avenue, Haddon Heights,
                                              New Jersey

1979 to present                  Clinical Assistant Professor of Medicine

                                              Thomas Jefferson University Hospital

                                              Philadelphia, Pennsylvania

1979 to present                  Chief, Division of Rheumatology

                                              Our Lady of Lourdes Medical Center,

                                              Camden, NJ

1978 – 1979                        Assistant Professor of Medicine

                                              Hahnemann Medical College,

                                              Philadelphia, PA

1980 to present                  Private Practice

                                              Midway Professional Center,

                                              Suite 101, 8 North White Horse Pike,

                                              Hammonton, NJ 08037

1976 – 1978                        Instructor in Medicine

                                              Temple University Hospital,

                                              Philadelphia, PA

Professional Memberships/Organizations:

American Medical Association

Camden County Medical Society

New Jersey State Medical Society

Philadelphia Rheumatism Society

New Jersey Rheumatism Society

American College of Rheumatology

American College of Physicians

International Society Clinical Densitometry

National Osteoporosis Foundation

Active

1974                                   New Jersey

1974                                   Pennsylvania

1974                                   Diplomate of the National Board
                                           of Medical Examiners

1976                                   Diplomate of the American Board
                                           of Internal Medicine

1984                                   Diplomate of the American Board of Internal 

                                           Medicine,  

                                           Subspecialty Rheumatology

2001, 2004                         Certified Clinical Densitometry, International 

                                            Society Clinical Densitometry

Current Hospital Staff Appointments:

1978 to present              Our Lady of Lourdes Medical Center, Camden, NJ

                                          Attending Physician

1980 to 2009                  Kessler Memorial Hospital, Hammonton, NJ

                                          Consultant in Rheumatology

1985 – 2004                    Cooper Hospital/University Medical Center,

                                          Camden, New Jersey

                                          Consultant in Rheumatology

Research Experience:

Asthma

Sponsor: Skye Pharma

Protocol: SKY2028-3-001

Phase: III

Year: 2005

A randomized, Double Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-center, 12 week study comparing the safety and efficacy of Fluticasone and Formoterol Combination (Fluti Form TM 100/10 ug twice daily) in a single inhaler (sky pharma HFA pMDI) with the administration of Placebo or Fluticasone 100 ug twice daily alone in adolescent and adult patients with mild to moderate asthma.

Chronic Low Back Pain

Sponsor: DOV
Protocol: DOV-075-020-US

Phase: III

Year: 2004

Double blind, placebo-controlled randomized study of Bicifadine in the treatment of Chronic Low Back Pain.

Sponsor: Johnson & Johnson

Protocol: R331333-PAI-3004

Phase: III

Year: 2006

A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.

Sponsor: Johnson & Johnson

Protocol: R331333-PAI-3011

Phase: III

Year: 2007

A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm with controlled Adjustments of Dose to Evaluate the Efficacy and Safety of CG5503 Extended Release (ER) in subjects with Moderate to Severe Chronic Low Back Pain.

Sponsor: Johnson & Johnson Protocol: R331333-PAI-3010

Phase: III Year: 2007

Open-Label Extension, Single Arm, Flexible-Dosing with CG5503 Extended-Release (ER) in subjects with moderate to Severe Chronic Pain.

COPD

Sponsor: Altana Pharma

Protocol: BY217-M2-124

Phase: III

Year: 2006

Effect of Roflumilast, on exacerbation rate in patients with COPD. A 52 week, Double-Blind Study with 500 mcg Roflumilast once daily versus placebo.

Fibromyalgia

Sponsor: Forest Research Institute

Protocol: MLN-MD-03

Phase: III

Year: 2006

A pivotal, multi center, double blind, randomized, placebo controlled monotherapy study of Milnacipran for the treatment of fibromyalgia.

Sponsor: Forest Research Institute

Protocol: MLN-MD-06

Phase: III

Year: 2006

A Multicenter, Open-Label, Flexible Dosing Study of Milnacipran for the treatment of Fibromyalgia.

Insomnia

Triazolam and Temazepam
Insomnia treatment study, comparing Triazolam and Temazepam.
 

Lupus

Sponsor: MedImmune

Protocol: MI-CP179

Phase: IIA

Year: 2008

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the safety and tolerability of multiple subcutaneous doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in subjects with Systemic Lupus Erythematosus.

Opioid-Induced Bowel Dysfunction

Mucosa Trial
Double   blind   study   evaluating   Cytotec   plus   NSAID   and   the   risk   of  GI
complications.

Sponsor: Glaxo Smith Kline

Protocol: SB-767905/011

Phase: II B

Year: 2003

Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.

Sponsor: Glaxo Smith Kline

Protocol: SB/767905-012/014

Phase: III

Year: 2003

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Alvimopan for 12 Weeks and 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.

Sponsor: Glaxo Smith Kline

Protocol: ABD104225

Phase:

Year: 2004

Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naive Subjects with Pain Treated with Opioid Therapy.

Sponsor: Wyeth

Protocol: 3200A3-200-WW

Phase: III

Year: 2006

A Multicenter, Randomized, Double-Blind, Parallel-Group, study of Oral MOA-728 for the treatment of Opioid-Induced Bowel Dysfunction in subjects with Chronic Non-Malignant Pain.

Osteoarthritis

Sponsor: Novartis

Study: Voltar

Phase: III

Twelve patients were enrolled for a clinical trial of Voltaren, a new NSAID.

Sponsor: Glaxo Smith Kline

Study: Nabumetone

Phase: III

Study comparing a new NSAID, Nabumetone, to another NSAID in a clinical trial.

Sponsor: Merck

Study: Rofecoxib

Phase: IIb/III

Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with osteoarthritis.

Sponsor: Merck

Protocol: 066-01

Phase: III

Year: 2002

A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.

Sponsor: Merck

Protocol: 071-01

Phase: III

Year: 2003

A 12 week, Randomized, Placebo and Active Comparator Controlled, Parallel Group, Double Blind Study to assess the safety and efficacy of Etoricoxib 30 mg verse Ibuprofen 2400 mg in patients with osteoarthritis.

Sponsor: Pain Therapeutics Inc.

Protocol: PTI-801-XH
Phase: III

Year: 2003

A Multi-center, Randomized, Double-Blind, Active- and Placebo-Controlled, Efficacy and Safety Study of Oxycodone HCI and Low Dose Naltrexone HCI in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.

Sponsor: Merck

Protocol: 077-00/COX553

Phase: III

Year: 2004

26 Week Randomized, Placebo-and Active-Comparator-Controlled, Parallel-Group, Double-Blind, Two Part study to assess the Safety and Efficacy of Etoricoxib vs. Celecoxib in Patients with Osteoarthritis.

Sponsor: Purdue Pharma

Protocol: OXY4003

Phase: IV

Year: 2004

Multicenter Usual Care Open-Labeled Randomized-Parallel-Group Trial Comparing the Impact of Therapy with Oxycontin vs. Usual Care in Moderate to Severe Osteoarthritis of the Hip or Knee.

Sponsor: Novartis

Protocol: VOSG-PN-310

Phase: III

Year: 2004

A 12 Week, Randomized, Double-Blind, Multicenter, Vehicle-Controlled, Parallel Group to Assess the Efficacy and Safety of the Diclofenic Sodium Gel 1% for the Relief of Signs and Symptoms in Patients with Osteoarthritis of the Knee.

Sponsor: Labopharm

Protocol: MDT3-005

Phase: III

Year: 2004

A Two-Arm study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the knee.

Sponsor: Merck

Protocol: MK-072-00

Phase: III

Year: 2005

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: MK-0663-066

Protocol: MK-0663-066

Phase: III

Year: 2005

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: Johnson & Johnson

Protocol: R331333-PAI-3004

Phase: III Year: 2006

A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.

Sponsor: Riant

Protocol: RN624-CL006

Phase: II

Year: 2006

A Randomized, Parallel-Arm, Placebo-Controlled, Double-Blind, Multiple Dose Study of the safety and efficacy of RN624 in adults with moderate to severe pain due to Osteoarthritis of the knee.

Sponsor: Biovail

Protocol: TMX-301

Phase: III

Year: 2006

An Open-Label, Long Term Safety Study of Tramadol Hydrochloride Extended Release and Meloxicam QD Combination in the Treatment of Moderate to Moderately Severe Pain Associated with Osteoarthritis.

Sponsor: Pfizer

Protocol: A3191172

Phase: IV

Year: 2006

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.

Sponsor: CombinatoRx

Protocol: CRX-102-006

Phase: II

Year: 2007

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to evaluate the efficacy of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.

Sponsor: CombinatoRx

Protocol: CRX-102-006E

Phase: II

Year: 2007

A Randomized, Double-Blind, Multi-Center, 1 year extension study to evaluate the long-term safety, tolerability and effectiveness of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.

Sponsor: Pfizer

Protocol: A4091025

Phase: III

Year: 2009

A Multi-Center, Randomized, Double-Blind, Controlled Study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with non-steroidal Anti-Inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with osteoarthritis of the knee or hip.

Osteoporosis

Sponsor: Merck

Protocol: MK-217

Phase: IV

Year: 2000

A Multicenter, Open Label, Randomized, Crossover, Preference Study of oral Alendronate Sodium 70 mg once weekly and 10 mg once daily in postmenopausal women with osteoporosis.

Sponsor: Eli Lilly & Company

Protocol: B3D-US-GHCQ:

Year: 2005

Direct assessment of non vertebral fractures in community experience (DANCE).

Rheumatoid Arthritis

Sponsor: Ortho-McNeil, Inc. Study: Ultram
 

A double blind, randomized, parallel group, multicenter comparison of the efficacy and safety of Mycophenolate mofetil p.o. (Xg b.i.d.) and placebo in patients with active rheumatoid arthritis (six month efficacy study) who are candidates for immunosuppressive therapy for rheumatoid arthritis.

Sponsor: Roche Study: Meloxicam
 

A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam with Naproxen and placebo on patients with rheumatoid arthritis.

Sponsor: Merck Study: Rofecoxib
 

Randomized double blind multicenter study evaluating the tolerability and
effectiveness of Rofecoxib versus Naproxen in patients with rheumatoid arthritis.

Sponsor: Wyeth Protocol: RADIUS 1

Year: 2002

Rheumatoid Arthritis DMARD Intervention and Utilization Study.

Sponsor: Merck

Protocol: 066-01

Phase: III

Year: 2002

A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.

Sponsor: Wyeth

Protocol: RADIUS 2

Year: 2003

Rheumatoid Arthritis DMARD Intervention and Utilization Study.

Sponsor: Merck

Protocol: MK-0663

Phase: III

Year: 2003 

A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib vs. Diclofenac Sodium in Patients with Rheumatoid Arthritis.

Sponsor: Hoffmann La Roche

Protocol: WA18063

Phase: III

Year: 2005

A randomized, double blind placebo controlled parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.

Sponsor: Arakis

Protocol: P-AD452-022

Phase: II

Year: 2005

A randomized, double-blind, multicenter, placebo controlled, dose ranging parallel group study to compare the efficacy, safety and tolerability of three strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking Methotrexate.

Sponsor: Hoffmann La Roche

Protocol: WA18696

Phase: III

Year: 2005

Long term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA Core Studies.

Sponsor: Merck

Protocol: MK-072-00

Phase: III

Year: 2005

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: MK-0663-066

Protocol: MK-0663-066

Phase: III

Year: 2005

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: Genentech

Protocol: U3384g

Phase: III

Year: 2006

A randomized, double blind, placebo controlled, multi center study of re-treatment with Rituximab in subjects with rheumatoid arthritis receiving background methotrexate.

Sponsor: Hoffmann La Roche

Protocol: WA17824

Phase: III

Year: 2006

A randomized, double blind, double dummy, parallel group study of the safety and efficacy of MRA monotherapy vs. methotrexate monotherapy, in patients with active rheumatoid arthritis.

Sponsor: Pfizer

Protocol: A3191172

Phase: IV

Year: 2006

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.

Sponsor: Genentech

Protocol: U3924g

Phase: III

Year: 2007

An Open-Label, Prospective Study of the safety of Rituximab in combination with other disease-modifying Anti-Rheumatic Drugs in subjects with Active Rheumatoid Arthritis.

Sponsor: Genentech

Protocol: WA20494/ACT3985g

Phase: III

Year: 2007

A Program investigating two dose regimens of Rituximab, two infusions of either 500 mg or 1000 mg separated by 14 days between treatments is underway in patients with Rheumatoid Arthritis unresponsive to Methotrexate and in patients with Rheumatoid Arthritis but naive to Methotrexate Treatment.

Sponsor: Genentech

Protocol: WA20495/ACT3986g

Phase: III

Year: 2007

A Randomized, Double-Blind, Parallel Group, International Study to evaluate the safety and efficacy of Ocrelizumab, compared to Placebo in patients with Active-Rheumatoid Arthritis who have inadequate response to at least one Anti-TNF a Therapy.

Sponsor: Pfizer

Protocol: A7701005

Phase: II

Year: 2007

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of CP-195543 and Celecoxib Dual Therapy in the treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are inadequately controlled on Methotrexate.

Sponsor: CombinatoRx

Protocol: CRX-102-007

Phase: II B

Year: 2007

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRX-102 over each of its components when given to subject with active Rheumatoid Arthritis.

Sponsor: Cypress

Protocol: CYP-D-001

Phase: N/A

Year: 2009

Applications for Methotrexate Optimization in Rheumatoid Arthritis.

Sponsor: Roche

Protocol: ML22533

Phase: IIIb

Year: 2009

An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic DMARDs in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs.

Sponsor: Roche

Protocol: WA19926

Phase: III

Year: 2009

A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe rheumatoid arthritis.

If you have any questions, please call 856-547-8004 or e-mail fisherresearch@markfishermd.com